This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Merrimack Pharmaceutical's MM-111 Granted Orphan Drug Status By FDA For Treatment Of Advanced Gastric And Esophageal Cancers

CAMBRIDGE, Mass., Aug. 13, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that the U.S. Food and Drug Administration's Office of Orphan Products Development has granted two separate orphan drug designations for its bispecific antibody, MM-111, for the treatment of esophageal cancer and for the treatment of gastric as well as gastroesophageal junction (GEJ) cancers.

"We are pleased that the FDA has granted orphan status designation for the development of MM-111 in these two indications," said Victor Moyo, MBChB., Vice President of Clinical Investigations at Merrimack Pharmaceuticals. "Patients with HER2-expressing gastric and esophageal cancers have limited treatment options. We are excited to move forward with the development of MM-111 and hope to positively impact the lives of these patients by addressing an unmet medical need."

MM-111 is designed to inhibit ErbB3 (HER3) receptor signaling in cancers that overexpress ErbB2 (HER2). Overexpression of the ErbB2 cell surface receptor has been reported in 7-34 percent of gastric cancers according to various scientific articles. Research has shown that ErbB3 expression is associated with poor prognosis in gastric cancer and may contribute to resistance to some current standard treatments. Currently, MM-111 is being tested in a Phase 2 study in advanced gastric, esophageal and gastroesophageal junction cancers.

These two orphan drug designations will potentially provide Merrimack Pharmaceuticals with 7-year marketing exclusivity for MM-111 and other benefits if the drug is approved by the FDA. The FDA's Office of Orphan Products Development is dedicated to supporting the development of products that are promising for treatment and diagnoses of diseases that affect less than 200,000 Americans annually.

About Merrimack Pharmaceuticals, Inc.               

Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of cancer. Merrimack applies its systems biology-based approach to biomedical research throughout the research and development process. Merrimack currently has six oncology therapeutics in clinical development.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,132.70 -81.72 -0.45%
S&P 500 2,104.50 -6.24 -0.30%
NASDAQ 4,963.5270 -24.3630 -0.49%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs